Shares of Tesaro (TSRO), an oncology-focused biopharma company, skyrocketed after the news that it has been working with advisors for a possible sale. The stock, which opened at $26.46 today, reached a maximum of $38.35 and jumped more than 30%. Because of the sudden spike, the trading of Tesaro shares was halted.
After Bloomberg reported that the company has been working with advisors for a possible sale, the stock skyrocketed and settled at $34.96 when the market closed on Friday. Last week on the same day, the stock plunged 19% after it released initial data from the Phase 1 AMBER study, which disappointed the investors.
Arena Pharmaceuticals soars on the $1.2 billion deal with United Therapeutics
Following the buyout report, Tesaro’s rival Clovis Oncology (CLVS) also increased and was up 8.48% at $16.75 when the market closed today.
On Tuesday, pharma giants AstraZeneca and Merck (MRK) announced that FDA will review their regulatory application with priority for the label expansion of its cancer treatment therapy. Encouraged by this announcement, Tesaro’s shares, which has got a cancer drug named Zejula, rose 8%.
When the company reported Q3 financial results two weeks ago, its earnings surpassed consensus views, while revenue missed the estimates. Tesaro posted a loss of $2.49 per share on revenues of $64.4 million.
TSRO stock has dropped 58% in the year-to-date period and 60% in the past 52 weeks. Shares of the Waltham, Massachusetts-based company hit a 52-week low of ($23.41) last Friday and the yearly high ($89.72) on November 16, 2017.
We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips
Most Popular
Microsoft (MSFT) reports higher revenue and profit for Q3 2024
Microsoft Corp. (NASDAQ: MSFT) on Thursday said its third-quarter 2024 earnings increased year-over-year, reflecting strong performance by the tech giant’s main operating segments. Third-quarter revenues came in at $61.86 billion,
GOOG, GOOGL Earnings: All you need to know about Alphabet’s Q1 2024 earnings results
Alphabet Inc. (NASDAQ: GOOG, GOOGL) reported its first quarter 2024 earnings results today. Revenues increased 15% year-over-year to $80.5 billion. Revenue growth was 16% in constant currency. Net income was
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales